P.A.W. Capital Corp Krystal Biotech, Inc. Transaction History

P.A.W. Capital Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 31, 2019	SELL	$27.2 - $41.2 $952,000 - $1.44 Million	-35,000 Closed	0 $0
Q1 2019 Apr 17, 2019	SELL	$19.86 - $32.9 $99,300 - $164,500	-5,000 Reduced 12.5%	35,000 $1.15 Million
Q4 2018 Feb 06, 2019	BUY	$15.03 - $25.38 $150,300 - $253,800	10,000 Added 33.33%	40,000 $831,000
Q3 2018 Oct 24, 2018	BUY	$14.43 - $21.0 $432,900 - $630,000	30,000 New	30,000 $527,000

297

24.3M

388K

233K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.93B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of P.A.W. Capital Corp, based on Form 13F filings with the SEC.

Stay updated on P.A.W. Capital Corp with notifications on news.